These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 24852682)

  • 1. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
    Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease.
    de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M
    Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
    Baumann TP; Duyar H; Sollberger M; Kuhle J; Regeniter A; Gomez-Mancilla B; Schmidtke K; Monsch AU
    Dement Geriatr Cogn Disord; 2010; 29(6):530-3. PubMed ID: 20606434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.
    Fortea J; Sala-Llonch R; Bartrés-Faz D; Lladó A; Solé-Padullés C; Bosch B; Antonell A; Olives J; Sanchez-Valle R; Molinuevo JL; Rami L
    Biol Psychiatry; 2011 Jul; 70(2):183-90. PubMed ID: 21514924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
    Wang ML; Wei XE; Yu MM; Li PY; Li WB;
    Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
    Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
    Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
    Solé-Padullés C; Lladó A; Bartrés-Faz D; Fortea J; Sánchez-Valle R; Bosch B; Antonell A; Molinuevo JL; Rami L
    Psychiatry Res; 2011 Jun; 192(3):140-6. PubMed ID: 21546220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
    JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
    Falgàs N; Ruiz-Peris M; Pérez-Millan A; Sala-Llonch R; Antonell A; Balasa M; Borrego-Écija S; Ramos-Campoy O; Augé JM; Castellví M; Tort-Merino A; Olives J; Fernández-Villullas G; Blennow K; Zetterberg H; Bargalló N; Lladó A; Sánchez-Valle R
    Hum Brain Mapp; 2020 Jun; 41(8):2004-2013. PubMed ID: 31944489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
    Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
    JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.